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Period (Per) genes are involved in the regulation of the circadian clock
and are thought to modulate several brain functions. We show that
Per2
Brdm1
 mutant mice display alterations in the glutamatergic system.
Lowered expression of the glutamate transporter Eaat1 is observed in
these animals, leading to reduced uptake of glutamate by astrocytes. As
a consequence, glutamate levels increase in the extra-cellular space of
Per2
Brdm1
 mutant mouse brains. This is accompanied by increased
alcohol intake in these animals. In humans, variations of the PER2 gene
are associated with the regulation of alcohol consumption.
Acamprosate, a medication used in the prevention of craving and
relapse in alcoholic patients is thought to act by dampening a hyper-
glutamatergic state. This drug reduced augmented glutamate levels and
normalized the drinking behavior in Per2Brdm1 mutant mice. Collectively,
these data establish glutamate as a link between the dysfunction of the
circadian clock gene Per2 and enhanced alcohol consumption.
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Across a spectrum of living organisms, ranging from cyanobacteria to humans, it has
been observed that biological functions follow a pattern of circadian rhythmicity.
These endogenous rhythms display a periodicity close to 24 hours in the absence of
environmental cues, thus reflecting the existence of an intrinsic biological clock. In
mammals, circadian rhythms in different tissues are coordinated by a master clock
located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus
1
. This
circadian clock is thought to be advantageous in synchronising physiological and
biochemical pathways, allowing the organism to anticipate daily changes, thus
ensuring better adaptation to the environment
2
.
The oscillatory mechanism of the circadian clock has been unraveled by
means of genetic analysis in Drosophila and mammals
3-5
. In the latter, the
heterodimeric complex of two transcriptional activators, CLOCK and BMAL1
(MOP3), induce the expression of several genes by interacting with the enhancer
elements, termed E-boxes, of their promoters. Amongst these genes are Per1, Per2,
Cry1 and Cry2, whose protein products, upon entering the nucleus, inhibit the activity
of the CLOCK/BMAL1 complex, and thereby generating an inhibitory feedback loop
driving recurrent rhythms in mRNA and protein levels of their own genes. This
molecular mechanism seems to be present in the local clocks of most tissues and brain
regions. Furthermore, these different clocks may then be synchronized by the SCN via
neural and endocrine outputs
6
.
Several lines of evidence implicate glutamate in the activation of receptors on
SCN neurons following retinal light perception
7
. This leads to the activation of
several signal transduction pathways and the clock genes Per1 and Per2
8
. At the
behavioral level, this results in an alteration of clock phase. Interestingly, mice mutant
in the Per2 gene (Per2
Brdm1
) display impaired clock resetting
9
, suggesting altered
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glutamate signaling. Here, we show that Per2
Brdm1
 mutant mice display alterations in
their glutamatergic system as the glutamate transporter Eaat1 (Excitatory Amino Acid
Transporter 1, also known as Glast) is found to be reduced in these mice. Excess
glutamate is cleared from the synaptic cleft by glutamate transporters
10
, located on
astroglial cells and transported back to the neuron via the glutamine-glutamate cycle.
A deficit in the removal of glutamate from the synaptic cleft, results in a hyper-
glutamatergic state and is suggested to produce alterations at the behavioral level
10,11
.
Importantly, a hyper-glutamatergic state has been implicated in the aetiology of
alcohol dependence
12-14
. We observe that in Per2
Brdm1
 mutant mice voluntary alcohol
consumption is enhanced. In humans we find an association between alcoholic
patients and genetic variations in the human PER2 gene. Acamprosate, a medication
thought to dampen a hyper-glutamatergic state in the alcohol dependent human
brain
15-17
 reduces augmented glutamate levels and normalizes enhanced alcohol
consumption in Per2
Brdm1
 mutant mice. These findings support the view that a hyper-
glutamatergic state can be involved in several aspects of alcohol dependence
12-14,18-20
.
RESULTS
Glutamate transporters in Per2Brdm1 mice
Wild type and Per2
Brdm1 
mutant mice differ in their behavioral response to a light
pulse administered at zeitgeber time (ZT) 14
9
 (ZT0 corresponds to lights on and ZT12
to lights off). Therefore, we set out to search for a difference in gene expression
between wild type and Per2
Brdm1 
mutant mice at ZT15. This time point has been
chosen because a strong induction of Per1 and Per2 gene expression in the SCN can
be observed one hour after light has been given
8
. Differential display analysis from
untreated wild type and Per2
Brdm1
 mutant mice should reveal the differences at the
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molecular level in the SCN of these animals and guide us to the molecular cause of
the observed behavioral variations of these two genotypes. Therefore, we subtracted a
cDNA library derived from Per2
Brdm1
 mutant mice at ZT15 from a cDNA library of
wild type littermate mice. We found that Eaat1, an important glutamate transporter,
which clears the synaptic cleft of glutamate and is solely expressed in astrocytes
10
, is
down-regulated at ZT15 in the brain and in the SCN of Per2
Brdm1
 mutant mice
(Fig.1a,b). Interestingly, Eaat1 mRNA is expressed in a diurnal manner in the SCN
of wild type mice (Fig. 1c), suggesting that the observed difference at ZT15 between
the two genotypes might represent a shift in diurnal expression. Therefore, we
monitored Eaat1 protein expression in whole brain extracts of wild type and Per2
Brdm1
mutant mice (Fig. 1d). We found that in wild type animals, maximal expression of
Eaat1 protein can be observed at ZT0 (24), while minimal expression can be seen
between ZT12 and ZT18 (P<0.0001). In contrast, Eaat1 protein levels were
significantly lower in Per2
Brdm1
 mutant mice as compared to wild type (P=0.0014).
We conclude that Eaat1 expression is reduced in Per2
Brdm1 
mutant animals and
therefore, these animals should exhibit elevated glutamate levels in the brain.
It is not clear how the mPer2 mutation leads to a reduced expression of Eaat1.
One kilobase of the Eaat1 promoter, containing a class II E-box, is not sufficient to
respond to Clock/Bmal1 (data not shown). Upstream of that E-box no additional E-
boxes were found. This suggests that regulation of Eaat1 by Per2 is of indirect nature,
through an unknown mechanism. It has been described that Eaat1 expression is
modulated by metabotropic glutamate receptors (mGluR)
21
. In Per2
Brdm1
 mutant mice,
protein levels of mGluR1, mGluR2/3 and mGluR5 did not differ from those in wild
type mice (Fig. 2a,b,c). This indicates that a change in Per2 function does not alter
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Eaat1 expression via the regulation of metabotropic glutamate receptor expression
21
.
However, we cannot exclude the possibility, that mGluR signaling is altered.
To keep glutamate levels in a range that is not toxic for the animals,
compensation for lack of Eaat1 is expected. We found a shift in expression of the
glutamate transporter Eaat2, also termed Glt-1, in Per2
Brdm1
 mutant mice (Fig. 2d).
The maximal expression is shifted from ZT6 in wild type animals to ZT18 in
Per2
Brdm1
 mutant mice. Two-way ANOVA revealed a significant difference between
genotypes (P=0.0051). However, the slight elevation of Eaat2 expression in Per2
Brdm1
mutant mice was not significant when the two expression curves were aligned
according to their maxima (ZT6 for wild type and ZT18 for Per2
Brdm1
 mutant mice).
Thus, although Eaat1 is low in Per2
Brdm1
 mutant mice, its reduction is not efficiently
compensated by up-regulation of Eaat2 to counteract a hyper-glutamatergic system in
Per2
Brdm1
 mutant mice. To further support this finding, we designed a set of
experiments to test whether Per2
Brdm1
 mutant animals exhibit elevated glutamate
levels in the brain.
Per2
Brdm1 mice have a hyper-glutamatergic brain
Eaat1 is one of the main glutamate transporters in the brain, responsible for clearing
glutamate accumulated in the synaptic cleft. Because Eaat1 protein is reduced in
Per2
Brdm1
 mutant mice, we expected glutamate levels to be elevated and comparable
to those of Eaat1 knockout animals
11
. Therefore, we performed a glutamate transport
assay with synaptosomes from total brain collected at ZT6, which yielded a similar
glutamate uptake in Per2
Brdm1
 mutant mice as compared to their wild type littermates
(Fig. 3a). The estimated Michaelis constant (Km) and the maximum uptake velocity
(Vmax) for wild type mice are: Km = 47 ± 15 M, Vmax = 1 ± 0.2 nmol/min/mg, and
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for Per2
Brdm1
 mutant mice Km = 32 ± 11 M, Vmax = 0.7 ± 0.1 nmol/min/mg. This
finding indicates that glutamate uptake in neurons is not altered in Per2
Brdm1
 mutant
mice because synaptosomes represent the pinched-off pre- and post-synaptic endings
of neurons. Further, we measured the intercellular amount of amino acids in the brain
of wild type and Per2
Brdm1 
mutant mice by assessing the amino acid concentration in
the supernatant of centrifuged brain homogenates. We found that Per2
Brdm1
 mutant
mice had significantly higher levels of intercellular amino acids as compared to the
wild type animals (P<0.0001) (Fig. 3b). A microdialysis experiment in the ventral
striatum of freely moving mice revealed that Per2Brdm1 mutant mice have glutamate
levels that are almost three-fold higher than levels in wild-type littermates (Fig. 3c).
Because Eaat1 is mainly localized on astrocytes
10
, we compared glutamate uptake in
these particular cells of both wild type and Per2
Brdm1
 mutant littermate pups,
sacrificed at ZT6. Cultured astrocytes of Per2
Brdm1
 mutant animals display a strongly
reduced uptake of glutamate as compared to astrocytes from wild type animals (Fig.
3d). The estimated Km and Vmax for wild type astrocytes are: Km = 20 + 12 M,
Vmax = 7.8 + 1.4 nmol/min/mg, and for Per2
Brdm1
 astrocytes Km = 48 + 40 M, Vmax
= 4.8 + 1.7 nmol/min/mg (two-way ANOVA of the curves reveals a significant
difference of glutamate uptake between the two genotypes, P=0.0007). This indicates
a deficit in glutamate clearance from the synaptic cleft in Per2
Brdm1
 mutant animals.
We do not know, whether this defect is directly or indirectly caused by the absence of
Per2. Whether Per2 influences astrocyte differentiation is not known, however,
astrocytes of Per2
Brdm1 
mutant mice and wild type animals cannot be distinguished
morphologically and both express the astrocyte marker, glial fibrillary acidic protein
(GFAP) (data not shown). Taken together, the results depicted in Figure 3
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demonstrate that glutamate levels are elevated in Per2
Brdm1
 mutant mice, due to a
malfunction of astrocytes, leading to a brain with a hyper-glutamatergic state.
Per2
Brdm1 mice voluntarily drink more alcohol
Enhanced glutamate levels and alterations within the glutamatergic system have been
implicated in excessive alcohol consumption and dependence
12-14,18-20
. Accordingly,
we proceeded to investigate voluntary alcohol consumption and preference
22
.
Per2
Brdm1
 mutant mice show significantly enhanced alcohol intake, when
pharmacologically relevant concentrations of 8-16% ethanol are offered (P=0.001;
two-way ANOVA) (Fig. 4a). At the highest concentration of 16%, Per2
Brdm1 
mutant
mice consume approximately 3-fold more ethanol than the wild type littermate control
animals. A similar observation was made on alcohol preference measures. Thus, at
concentrations of 8-16% ethanol, a clear genotype dependent difference is observed
(P=0.001) (Fig. 4b).
There are different explanations why Per2
Brdm1 
mutant mice drink more
alcohol. One obvious explanation is that through alterations in the glutamatergic
system, energy need is enhanced and, therefore, more alcohol is consumed. However,
this explanation seems unlikely as no genotype dependent differences are observed at
low ethanol concentrations (2-4%) (Fig. 4a,b). Moreover, food consumption does not
differ between the two genotypes (mean daily average food intake over a period of 14
days: wild type 152 ± 6 g/kg, and Per2
Brdm1 
mutant mice 167 ± 12 g/kg body weight).
Alternatively, the increase in alcohol consumption in Per2
Brdm1
 mutant mice
could be due to an alteration in taste sensation of these animals. Therefore, we
estimated the preference ratio for a bitter tasting compound containing various
concentrations of quinine
22,23
. Both genotypes behave similarly (Fig. 4c) and in a
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sucrose preference test, where the sweet component is estimated, again no differences
between genotypes, are observed (Fig. 4d). Thus, a difference in taste sensation
probably does not account for an enhanced alcohol preference in Per2
Brdm1
 mutant
animals. Because sucrose consumption does not differ between genotypes, energy
consumption is the same and hence, an increase in alcohol uptake in Per2
Brdm1
 mice is
probably not caused by higher caloric needs in these animals.
However, one could argue that alcohol metabolism and elimination is altered
in Per2
Brdm1 
mutant mice. Alcohol is mainly eliminated via oxidation, catalyzed by
alcohol dehydrogenase
24
. Circadian variations in plasma ethanol levels and within
alcohol oxidation pathways have been described in mice
25
. Therefore, it can be
assumed that in Per2
Brdm1 
mutant mice – the mPer2 gene is also strongly expressed in
the liver – alcohol elimination may differ and that the observed changes in alcohol
drinking behavior can be simply explained by alterations in the ethanol elimination
rate. Therefore, we studied blood alcohol elimination in both alcohol-naïve and
alcohol-experienced Per2
Brdm1
 mutants as well as their wild type littermates. Under
none of these conditions differences in blood alcohol concentrations between
genotypes were observed (Fig. 4e,f) excluding the possibility that altered alcohol
elimination accounts for an enhanced alcohol consumption in Per2
Brdm1
 mutant mice.
A final and likely explanation, is that a mutation in mPer2, influences the set
point within the reinforcement system. Thus, the reinforcing value of alcohol might be
differently perceived by Per2
Brdm1 
mutant mice as compared to wild type animals.
Therefore, we studied the reinforcing properties of alcohol in Per2
Brdm1
 mutant mice,
conducting operant self-administration using a two-lever paradigm. Following
acquisition of lever responding using a simple fixed ratio schedule of 1 (FR1 i.e. one
lever press resulted in the delivery of one drop of alcohol), Per2
Brdm1
 mutant mice
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exhibited approximately 50 lever responses within a 30 minute session, whereas wild
type mice responded significantly less (P=0.02; approximately 25 lever responses per
session (Fig. 5a)). Moreover, while FR1 performance is more related to the rewarding
post-consumptional consequences of the delivered reinforcer, progressive effort
requirements better reflect incentive-motivation processes
26
. Accordingly, we used a
progressive ratio (PR) schedule to study the incentive motivation for alcohol drinking
in Per2
Brdm1
 mutant mice. Using a PR2 (response requirements increased by a step
size of 2), the breakpoint for alcohol responding was significantly higher in Per2
Brdm1
mutant animals as compared to the wild type mice (P=0.02) (Fig. 5b).
Together, we conclude from this set of experiments that neither the caloric
value, nor taste differences, nor variations in alcohol elimination can account for the
enhanced alcohol intake we clearly observed in Per2
Brdm1
 mutant mice. Rather, we
suggest that it is possibly due to alterations in the brain reinforcement system of
Per2
Brdm1
 mutant mice, thus driving an enhanced incentive motivation to consume
more alcohol than the littermate control animals. To further translate this conclusion
to a neurochemical level, we propose that through a reduction of Eaat1, enhanced
glutamate levels in the brain reinforcement system lead to a hyper-glutamatergic state,
finally accounting for the observed “alcohol phenotype”. This conclusion is further
supported by a recent finding, which shows that glutamate transport is reduced in the
cerebral cortex of alcohol-preferring AA rats
27
.
Acamprosate treatment of Per2Brdm1 mice
Acamprosate is used in the clinic for relapse prevention
28
. A meta-analysis of 20
clinical trials clearly shows its effectiveness
29
, however, the exact mechanism of how
acamprosate diminishes alcohol consumption and reduces the likelihood of relapse is
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still not clear. Different neurobiological pathways have been implicated in the
aetiology of alcohol dependence and one pathway seems to involve the glutamatergic
system
16,18,30,31
, where chronic alcohol intake leads to compensatory changes. It is
suggested that acamprosate acts mainly on a hyper-glutamatergic state, yet having
only little effect on a “normal” glutamatergic state
15-17,32,33
. Due to the occurrence of a
hyper-glutamatergic system in Per2
Brdm1
 mutant mice, we speculated that acamprosate
should be more effective in reducing glutamate levels and alcohol consumption in the
mutant rather than in wild type mice. Indeed, after performing further in vivo
microdialysis experiments, we observed that 80 minutes following acamprosate
treatment, extracellular glutamate levels in the nucleus accumbens in Per2
Brdm1
 mutant
mice no longer differed from those in wild type mice (Fig. 6a). Furthermore,
following acamprosate treatment, Per2
Brdm1
 mutant mice exhibited reduced levels of
alcohol consumption, even below those of wild type animals (Fig. 6b). These
experiments show that the “hyper-glutamatergic endophenotype” as well as the
“alcohol phenotype” in Per2
Brdm1
 mutant mice can be rescued by acamprosate
treatment. As acamprosate was previously shown to block enhanced extracellular
dopamine levels in the nucleus accumbens after glutamate receptor stimulation
34
, it is
suggested that dopamine-mediated alcohol reinforcement processes
35 
are influenced
by acamprosate through the dampening of a hyper-glutamatergic tonus.
Genetic variations of human PER2 and alcoholism
Based on the findings of the animal studies discussed above, we carried out an
exploratory analysis of a possible association of the amount of alcohol intake and a
PER2 genotype in human alcohol dependent subjects. We performed a search for
single nucleotide polymorphisms (SNPs), which was based on sequencing of the
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exons, exon-intron boundaries and regulatory domains of the PER2 gene. We
identified 11 gene variations (9 SNPs, 2 deletions), one of which is in the 5’regulatory
region, one in the 5’UTR, one in the 3’UTR and 8 in introns. Figure 6c shows the
genomic organization of the PER2 gene, sequenced regions and position of the
genetic variations, as well as characteristics of each SNP.
We selected 6 informative SNPs with a minor allele frequency >0.05 for
genotyping in a sample of 215 patients with a detailed assessment of alcohol intake
according to the SSAGA questionnaire
36
. After performing a split to compare high
(300 g/d) vs. low alcohol intake (<300 g/d)37, we found a significant association of
high vs. low alcohol intake with SNP 3 (p=0.02, OR 0.46), with allele G being a
protective allele (Supplementary Table 1 online). In order to assess the individual
contribution of each SNP to the phenotype observed we performed a stepwise
regression analysis by forwarding, which identified SNP 3 as the only relevant co-
variable. To assess phase information, we then performed a haplotype analysis. Since
there was an exactly similar distribution of SNPs 2 and 5 as well as SNPs 9 and 11,
we excluded SNPs 2 and 11 from further analysis. The remaining haplotype
consisting of SNPs 3-4-5-9 showed a significant association between high vs. low
amount of alcohol intake (global P-value by permutation test = 0.03)
(Supplementary Table 2 online). Analysis of individual haplotypes identified a
haplotype G-C-C-C, which was significantly more frequent in patients with low
alcohol intake (P=0.0075, OR 0.42). The results of our regression analysis suggest
that SNP 3 is the main contributor to a possible biological effect of the genotypes
analyzed.
In order to generate hypotheses for a possible functional role of SNP 3, we
first performed a phylogenetic footprint analysis, which showed that SNP 3 is
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embedded in a CATTTT motive, preserved in humans, chimpanzees and rats. We also
found that SNP 3 is located in an enhancer-like structure in intron 3, containing
transcription factor binding sites known to be expressed in the human brain. In a
sequence 4 bases upstream and 14 bases downstream of the SNP, we found
transcription factor binding motives for NFB, Sp1, c-myb, E47 and IL-6 RE-BP.
SNP 3 alters the binding motives for Sp1, c-myb and NFB, suggesting a possible
regulatory function of this SNP in transcriptional activation of PER2. Thus, our
findings support the results of the studies in Per2 mutant mice and suggest a role of
the PER2 gene in the regulation of alcohol consumption in humans.
DISCUSSION
In this study we report about the relationship between a non-functional Per2 gene and
the glutamate transporter Eaat1, which leads to elevated glutamate levels in the brain.
These elevated glutamate levels cannot be compensated through adaptive up-
regulation of Eaat2 and hence a hyper-glutamatergic brain in Per2
Brdm1
 mutant mice is
the consequence. At the behavioral level, this leads to increased alcohol consumption
in the mutant mice. Furthermore, we provide evidence for an analogous function of
PER2 in regulating alcohol intake in humans. Thus, the amount of alcohol
consumption in alcoholic patients is associated with haplotypes of the PER2 gene. In
conclusion, we suggest that altered function of the PER2 gene leads to changes in
alcohol reinforcement processes. This is in line with other reports showing that per
mutant flies as well as Per1 and Per2 mutant mice exhibit changes in cocaine and
morphine sensitization and reward
38-40
, suggesting that clock genes seem to be
involved in common modulator mechanisms of drug abuse-related behaviors
41
.
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Interestingly, also methamphetamine injection causes an increase of Per gene
expression in the caudate putamen of the mouse
42,43
.
Enhanced alcohol consumption in Per2
Brdm1
 mutant mice can be rescued
pharmacologically by the anti-craving and anti-relapse compound acamprosate. Thus,
following acamprosate treatment, Per2
Brdm1
 mutant mice had reduced levels of alcohol
consumption, which dropped even below those of wild type animals. This compound
also reduced glutamate levels in the nucleus accumbens – an effect, which was not
observed in wild type mice, suggesting that acamprosate acts mainly on alcohol
drinking by dampening the hyper-glutamatergic tonus in Per2
Brdm1
 mutant mice.
Evidence for a genetic basis of a hyper-glutamatergic system in humans is provided as
seen by the differential response to acamprosate in alcoholic patients. It should be
noted that compared to placebo, acamprosate treatment increases abstinence rates
only by 10-20%
28,29
. However, on a diagnostic level, responders and non-responders
cannot be differentiated. We hypothesize that genetic variations in the PER2 gene
may aid in the identification of alcohol dependent patients responsive to acamprosate
treatment. In addition to this suggested treatment improvement, our study points to
pathological consequences, when proper function of a circadian gene is disrupted.
This is supported by reports that indicate enhanced alcohol consumption in shift
workers and people suffering from severe jet lag, as found for example in air craft
staff
44,45
. Hence, alterations in PER2 and associated changes in the glutamatergic
system may underlie those pathological consequences, suggesting one possible
pathway in the aetiology of alcohol dependence.
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METHODS
Animals. The mice used in this study have been characterized previously46. The wild
type and Per2Brdm1 mutant animals used in this study were littermates derived from
intercrosses between heterozygous Per2Brdm1 mice on a 129SvEvBrd/C57BL/6-Tyrc-Brd
background. Animal experiments were approved by the veterinary offices of Fribourg
and Mannheim.
Tissue preparation and cDNA synthesis. Mice held for at least two weeks in a 12h
light/12h dark cycle, were sacrificed at ZT 15. Tissue collection and cell-lysis were
carried out under dim red-light (15W). cDNA synthesis was performed using the
SMART PCR cDNA Synthesis Kit (Clontech K 1052-1) according to the
manufactures instructions.
Subtraction and amplification of differentially expressed genes. The PCR Select
cDNA Subtraction Kit (Clontech K1804-1) was used for substraction and
amplification of differentially expressed genes. PCR-Products were cloned into the
pCR II-TOPO vector with the TOPO TA Cloning Kit (Invitrogen K4600-40).
Northern blot analysis. Northern analysis was performed using denaturing
formaldehyde gels with subsequent transfer to Hybond-N membrane (Amersham).
cDNA probes had a specific activity of 10
8
 cpm/g. Signals were quantified using
Quantity One 3.0 software (Bio-Rad).
Western blot analysis. Brain proteins were resolved by SDS-PAGE and transferred
to PVDF membranes (Amersham). Antibodies used for detection were: rabbit Eaat1-
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specific antibody diluted 1:1000 (Abcam, Cambridge, ab 416), Eaat2 (Alpha
Diagnostics, # GLT-1 1-A), mGluR1, mGluR5 (Upstate, #06-310 and #06-451) and
mGluR 2/3 (Novus Biologicals, NB 300-126). Secondary antibodies were: goat anti-
rabbit IgG-HRP diluted 1:5000 for Eaat1 (Sigma, A5420) and mGluR5 and goat anti-
rabbit IgG-AP 1:5000 (Pierce, # 31340).
Ninhydrin assay. 2 ml of ninhydrin solution (0.2% in ethanol) was added to 2 ml
synaptosomal supernatants and the mixture was boiled for 15 min in a water bath. The
tubes were cooled to room temperature and absorbance was measured at 570 nm.
Synaptosomes and glutamate uptake. Brain tissue of wild type and Per2Brdm1 mutant
mice was homogenized. Aliquots of synaptosomes were added to incubation buffer
containing L-[3H] glutamic acid (Specific activity 51 Ci/mmol: Perkin Elmer Life
Sciences Inc.). The reaction was terminated (incubation buffer in which an equimolar
concentration of choline chloride was substituted for NaCl). The 3H-bound
radioactivity was determined by liquid scintillation counting (PACKARD liquid
scintillation analyzer TRI-CARB 2200CA).
Glial cells and glutamate uptake. Glial cells were obtained from postnatal day (P) 1
brains of wild type and Per2Brdm1 mutant pups. The tissue was dissociated by
trituration and the cells were plated and passaged. After the second passage, cells
were counted and seeded into 24-welled plates. Glutamate uptake was performed as
described in Supplementary Methods online.
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Microdialysis and determination of glutamate levels. The CMA/7 guide cannula
with a dummy was implanted into the ventral striatum. After the implantation, the
mice were placed in the CMA/120 system for freely moving and connected via a
collar to a swivel. The CMA/7 microdialysis probe was inserted into the guide
cannula and perfused at a constant flow rate of 2 µl/min. One day after the recovery,
microdialysis experiments were carried out in freely moving mice between ZT3 and
ZT6. As previously described in detail47, glutamate levels were determined from 15-
µL of each dialysate sample.
Determination of blood alcohol levels. Alcohol-naïve and alcohol-experienced wild
type and Per2Brdm1 mutant mice were injected i.p. with 3.5 g/kg ethanol. Blood alcohol
content was determined using the NADH enzyme spectrophotometric method
(Greiner AG).
Alcohol self-administration and pharmacological treatment. After one week of
habituation to the animal room, male Per2Brdm1 mutant and control mice were given
continuous free access to two bottles of tap water for 3 days, followed by tap water
and 2% (v/v) ethanol solution for another 3 days (Days 1-3). Ethanol consumption
was calculated in terms of g of ethanol consumed/kg of body weight/day (g/kg/day).
In a second batch of mice, we tested the effects of acamprosate treatment. Two daily
injections of acamprosate (200 mg/kg, every 12:00 h) were given to all mice and
drinking data were compared to those of the four last days of the baseline.
Operant ethanol self-administration and PR measurements. Experiments were
performed during the active phase in operant chambers (TSE Systems) equipped with
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two levers, only one being active, and individual sessions lasting 30 minutes. Animals
were trained to orally self-administer ethanol (10%) after having undergone a
standard sucrose fading procedure under a fixed ratio 1 (FR1) paradigm. Mice were
also tested on a progressive-ratio (PR) schedule for ethanol (10%) reinforcement, in
which the response requirements increased by a step size of 2. The final ratio
completed was defined as the breaking point.
Taste preference tests. Alcohol-naïve and alcohol-experienced mice were used for
these tests. Sucrose (0.5, 2.5, and 5% w/v) and quinine (5,10, and 20 mg/dl) solution
intake was measured in a two-bottle free choice test (sucrose or quinine against
water). A test lasted for 9 days and bottles were weighed every 3 days along with the
position of the bottles being changed.
Subjects and psychiatric assessment. 215 patients of German origin (172 males, 43
females; mean age 41.3 years, SD 8.4) were recruited by the Department of
Psychiatry of the University of Munich. All patients were consecutively admitted for
an in-patient alcohol withdrawal therapy and fulfilled the DSM-IV criteria for alcohol
dependence. Symptoms related to alcohol taking behaviour were assessed in using the
semi-structured assessment for the Genetics of Alcoholism (SSAGA)36. To distinguish
patients with low vs. high alcohol intake, a cut-off was set at 300 g/d, ensuring
comparability of the results with previous work on genes regulating glutamatergic
neurotransmission37. Written informed consent was obtained from all individuals,
when they were in a state of full legal capacity. The study was approved by the ethics
committee of the University of Munich.
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Mutation screening and promoter analysis. Identification of SNPs was performed
by sequencing 32 Caucasian DNA samples. For details see Supplementary Methods
online.
Genotype analysis. DNA was prepared from whole blood with standard salting out
methods. Six Single-nucleotide polymorphisms in the PER2 gene were genotyped
using the TaqMan MGB biallelic discrimination system.
Association analysis and haplotype analysis. The P-values of genotypes reported
refer to the two-sided trend test for 2x3 contingency tables as originally proposed by
Armitage48. Haplotype association analyses were performed with COCAPHASE 2.35
(see web adresses).
Web addresses: COCAPHASE 2.35
 
www.hgmp.mrc.ac.uk
Note: Supplementary information is available on the Nature Medicine website.
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Figure Legends
Figure 1 Expression of the glutamate transporter Eaat1 in brain tissue. (a)
Northern blot analysis showing reduced levels of Eaat1 mRNA at zeitgeber
time (ZT) 15 in brain tissue of Per2Brdm1 mutant mice. Loading control: Gapdh
mRNA. (b) Expression of Eaat1 mRNA revealed by in situ hybridization is
reduced at ZT15 in the SCN of Per2Brdm1 mutant mice. (c) Temporal profile of
Eaat1 mRNA in wild type SCN revealed by in situ hybridization. (d) Western
blot analysis: temporal profile of Eaat1 protein relative to actin in brain of wild
type (wt) and Per2Brdm1 mutant mice. Representative blots are shown at the
bottom. Each value is the mean + S.E.M. of 3 animals. Data of ZT0 are
plotted twice (ZT0 and ZT24). * indicate significant difference from wild type
mice (P<0.05). Scale bar = 500 m.
Figure 2 Protein levels of mGluR1,2,3,5 and Eaat2. Western blot analysis of
wild type (wt, solid line) and Per2Brdm1 mutant (hatched line) mouse brains
over 24 hours. (a) mGluR1, no significant difference can be seen, (b)
mGluR2/3, no difference is detected between the two genotypes, (c) mGluR5
is similar in Per2Brdm1 mutant and wild type mice. (d) Eaat2 expression is
shifted in Per2Brdm1 mutant mice. Values are shown as mean + S.E.M. of three
animals per time point. Data of ZT0 are plotted twice (ZT0 and ZT24).
Photographs below the plots depict representative Western blots with the
corresponding actin controls (bottom, labeled A). * indicate significant
difference from wild type mice (P<0.05)
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Figure 3 Glutamate levels in brain tissue and glutamate uptake by astrocytes.
(a) Glutamate transport in synaptosomes of wild type and Per2Brdm1 mutant
mice sacrificed at ZT6. Values are mean ± S.E.M of 3-4 animals per
datapoint. (b) Ninhydrin assay to determine amount of amino acids in
extracellular space in adult brains collected at ZT6. Values are presented as
mean ± S.E.M. (*P=0.001, n=6). (c) Mean basal levels of glutamate
determined from extracellular dialysates of the ventral striatum (n=6-7 mice
per group). The basal levels of glutamate are expressed in M/15l dialysate
and the mean of 6 fractions collected was calculated. *P=0.005 compared to
wild type mice. (d) Glutamate uptake of cultured astrocytes harvested at ZT6
of postnatal day 1 pups. Values are mean ± S.E.M of 3 animals per datapoint.
Two-way ANOVA reveals a significant genotype effect, P=0.0007.
Figure 4 Intake and preference of different alcohol solutions at increasing
concentrations of Per2Brdm1 mutant mice and wild type (wt) littermate mice. (a)
Drinking data are depicted as the mean ± S.E.M. ethanol intake in g/kg/day as
averaged over a 3 days period for each concentration. Two-way ANOVA for
alcohol intake revealed a significant interaction between the genotypes and
the different concentrations of alcohol (2-16% w/v; P=0.001). The analysis
also showed a significant genotype effect (P=0.001) (b) Ethanol preference
over water. Per2Brdm1 mutant mice exhibited a significant enhanced preference
for alcohol (P=0.001) compared to wild type littermates if ethanol
concentration was more than 8%. (c, d) Taste sensation was assessed using
quinine (c) and sucrose (d) preference. The animals were allowed to choose
in the home cage from two bottles: one of them containing tap water and the
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other sucrose (0.5-5%; (w/v) and quinine (5-10 mg/dl), respectively. The free
choice procedure lasted 9 days and the solutions were changed every third
day. (e, f) Levels of ethanol in blood samples were determined at several
times (30,60,120 and 240 min) after the i.p. injection of ethanol (20%v/v) at a
dose of 3.5 g/kg body weight. No differences between genotypes at any time
after the injection could be detected in alcohol-naïve (e) and alcohol-
experienced mice (f). All data are mean values ± S.E.M., group sizes were
n=8-18 depending on the experiment. * indicates significant differences
between genotype (P<0.001).
Figure 5 Operant ethanol self-administration and progressive ratio
measurements in Per2Brdm1 mutant mice and wild type littermates. (a) Mice
were trained to respond to an FR1 for alcohol (fixed ratio schedule of 1, i.e.
one lever press results in the delivery of one drop of alcohol), using a sucrose
fading procedure, until reaching a stable response rate for a 16% ethanol
solution. A two-way ANOVA revealed an effect of genotype [F(1,12)= 6.62;
P<0.02] but the factor day and the group x day interaction failed to reach
significance, revealing that Per2Brdm1 mutant mice displayed a significantly
higher number of responses at the active lever than WT mice across all
sessions. (b) Two days later, an additional self-administration session under a
progressive ratio schedule (step size=2) was conducted. A Student’s t test for
independent samples showed that both groups of animals differed in the
number of responses at the active lever, which resulted in a significant
difference [t (12)= 2.83; P< 0.02] in the break point for each group.
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Figure 6 Effects of acamprosate on extracellular glutamate levels and on
alcohol consumption in Per2Brdm1 mutant mice and wild type littermates.
Schematic representation of the human PER2 (GI:1365471) gene. (a)
Glutamate was determined in extracellular dialysates of the ventral striatum
(n=6-7 mice per group). The microdialysis data obtained after acamprosate
injection (200 mg/kg i.p.) are expressed as the percentage of basal values
from wild type mice and were analysed by ANOVA for repeated measures. (b)
Pharmacological rescue by acamprosate of augmented drinking behaviour in
Per2Brdm1 mutant mice. Two daily injections of acamprosate (200 mg/kg i.p.)
for 4 days (arrows) produced a complete rescue of drinking behaviour in
Per2Brdm1 mutant mice. To better illustrate this effect, alcohol intake data of
both groups of mice were transformed into a percentage measure of group
differences. The ANOVA results revealed an effect of the factor group
[F=13.70, P<0.01] and the factor day [F= 3.59; P<0.01] as well as a significant
interaction between these factors [F= 3.60; P<0.01], showing that during the
acamprosate treatment period, the differences between groups disappeared.
(c) Genomic organization of the human PER2 gene with 23 exons (green
rectangles with Roman numerals) and 22 introns is shown (horizontal lines,
not drawn to scale). Single Nucleotide Polymorphisms (SNPs, continous
arrows) or Insertion/Deletion (dotted arrow) are identified with Arabic
numerals and described in orange (SNPs selected for genotyping) or white
(SNPs not selected for genotyping) boxes. The second line in each box
indicates the base pair exchange, the third line indicates the position of the
SNP relative to the ATG site and the fourth line indicates the frequency of the
NM A22834 (Albrecht)
31
minor allele. Despite its informative allele frequency, SNP 8 was not analysed
due to genotyping problems.






SUPPLEMENTARY METHODS
Animals
The mice used in this study have been characterized previously47. Per2Brdm1 mutant
mice have 87 amino acids deleted in the PAS domain of the Per2 protein which leads
to a dramatic reduction of the Per2 mRNA and protein in cells. The wild type and
Per2Brdm1 mutant animals used in this study were littermates derived from intercrosses
between heterozygous Per2Brdm1 mice on a 129SvEvBrd/C57BL/6-Tyrc-Brd background.
Animal experiments were approved by the veterinary offices of Fribourg and
Mannheim.
A. Molecular methods
Tissue preparation and cDNA synthesis
Mice held for at least two weaks in a 12h light/12h dark cycle were sacrificed at ZT
15. The SCN of 6 wild type and 6 Per2Brdm1 mutant mice were collected in 1ml of
RNAzol (Wak Chemie, WAK-CS-105) and RNA isolation was performed according
to the manufacturers instructions. Tissue collection and cell-lysis were carried out
under dim red-light (15W). cDNA synthesis was performed using the SMART PCR
cDNA Synthesis Kit (Clontech K 1052-1) according to the manufactures instructions.
In brief, 1 µg of total RNA were used for First-Strand cDNA Synthesis with 200U of
Superscript II reverse transcriptase (Gibco BRL M-3516) in a final volume of 10 µl.
cDNA was stored at –20°C and 2 µl were used for amplification by long distance
PCR (LD-PCR) using the primers supplied in the kit. The reaction was performed in a
total volume of 100 µl for 20 cycles with the following parameters : 95°C (initial
denaturation) for 2 min, denaturation at 95°C for 5 s, annealing at 65°C for 5 s and
extension at 68°C for 6 min. For each sample (wild type, mutant and control) 600 µl
of cDNA were prepared and directly purified by phenol:chloroform:isoamyl alcohol
(25:24:1) extraction and concentrated by n-butanol treatment to a volume of 60µl. The
cDNA was further purified on a CHROMA SPIN-1000 column and finally eluted in
two steps with 320 µl and 75 µl of TNE (10mM Tris-HCl, pH 8, 10mM NaCl, 0,1mM
EDTA). Eluates were combined, directly digested with 10U of Rsa I for 3h, purified
on an QIAquick column (Qiagen 28106) and eluted in 50 µl of TE. The digested
cDNA was precipitated with ammonium acetate, washed with 80% ethanol and air
dried. The pellet was dissolved in 6,7 µl of TNE and the concentration was adjusted to
300ng/µl.
Subtraction and amplification of differentially expressed genes
The PCR Select cDNA Subtraction Kit (Clontech K1804-1) was used for substraction
and amplification of differentially expressed genes. In brief, 1 µl of digested cDNA
from SCN tissue from wild type mice (tester population) was diluted in 5 µl of ddH20.
2µl of this dilution were ligated to either adaptor 1 or adaptor 2R provided with the
Kit in a final volume of 10µl overnight at 16°C. Subtractive hybridization was
performed in two steps as outlined in the manual. Briefly 1,5µl of digested cDNA
from Per2Brdm1 mutant mice (driver population) where mixed with 1,5µl of tester
cDNA (wild type), ligated to either adaptor 1 or adaptor 2R, in hybridization buffer
and hybridized at 68°C for 8h. The second hybridization was carried out by addition
of 1µl of fresh driver cDNA and subsequent incubation at 68°C overnight. The
samples were diluted in 200µl of dilution buffer and stored at –20°C. Amplification of
differentially expressed sequences was carried out in two steps as described in the
manual. For primary PCR ( 27 cycles) 1µl of the diluted, subtracted sample was used.
The PCR product of the primary PCR was diluted 1:10 and 1µl was used for
secondary PCR with 10 cycles. PCR-Products were cloned into the pCR II-TOPO
vector with the TOPO TA Cloning Kit (Invitrogen K4600-40). Positive clones were
selected by digestion with EcoRI and sequenced on a Perkin Elmer ABI PRISM 377
DNA-Sequencer.
Northern blot analysis
Northern analysis was performed using denaturing formaldehyde gels with
subsequent transfer to Hybond-N membrane (Amersham). For each lane 20g of total
RNA were loaded. Labeling of cDNA probe was done using the random prime
labeling kit (Pharmacia) incorporating [
32
P]dCTP to a specific activity of 10
8
 cpm/g.
Blots were exposed to X-ray films (Hyperfilm MP, Amersham) for 72 h, and signals
were quantified using Quantity One 3.0 software (Bio-Rad). Signal intensities were
normalized to the 28S rRNA.
Western blot analysis
Brain proteins were resolved by SDS-PAGE (EAAT1, Eaat2, 10% ; mGluR1,
mGluR2/3, mGluR5, 6%) and transferred to PVDF membranes (Amersham).
Membranes were blocked with 5% non-fat milk in PBS pH 7.4 and were incubated
with an Eaat1 specific antibody diluted 1:1000 (Abcam, Cambridge, ab 416) for 2 h at
room temperature. Eaat2 (Alpha Diagnostics, TX, # GLT-1 1-A), mGluR1, mGluR5
(Upstate, NY, #06-310 and #06-451) and mGluR 2/3 (Novus Biologicals, Littleton,
CO, USA, NB 300-126) were diluted 1:1000 and incubated at 4°C overnight. The
membranes were washed with PBS, followed by PBST and incubated with goat anti-
rabbit IgG-HRP diluted 1:5000 for Eaat1 (Sigma, A5420) and mGluR5 and goat anti-
rabbit IgG-AP 1:5000 (Pierce, Rockford, IL, # 31340) for the remaining 2h at room
temperature. The membranes were washed repeatedly and the proteins were detected
using the ECL western blotting detection reagents and analysis system (Amersham,
RPN 2209) for Eaat1 and mGluR5. Alkaline Phosphatase reaction with BCIP/NBT
(Interchim, Montlucon, France, UP099851) was used for the remaining.
B. Biochemical methods
Ninhydrin assay
Synaptosomal supernatants from the wild type and Per2
Brdm1
 mutant mice were
assayed using the ninhydrin reagent to assess the intercellular amino acids levels.
Briefly, 2ml of ninhydrin solution (0.2% in ethanol) was added to 2ml synaptosomal
supernatants and the mixture was boiled for 15 min in a water bath. The tubes were
cooled to room temperature and absorbance was measured at 570 nm.
Synaptosomes and glutamate uptake
Brain tissue of wild type and Per2
Brdm1
 mutant mice was homogenized at 4°C in 25
volumes (wt/vol) of 0.32 M sucrose with a glass homogenizer (Heidolph RZR 2102
control, Germany) fitted with a Teflon pestle. The homogenate was centrifuged at 200
g for 10 min, and the supernatant was centrifuged at 20,000 g for 20 min. The pellet
was resuspended in 0.32 M sucrose and centrifuged at 20,000 g for 20 min. The crude
synaptosomal pellet was finally resuspended in 3 ml of 0.32 M sucrose and used for
the glutamate uptake assays. 25-l aliquots of synaptosomes were added to 250 l of
incubation buffer (5 mM Tris, 10 mM HEPES, 2.5 mM KCl, 1.4 M NaCl, 1.2 mM
CaCl2, 1.2 mM MgCl2, 1.2 mM K2HPO4, and 10 mM dextrose, pH 7.4) containing L-
[
3
H] glutamic acid ( Specific activity 51 Ci/mmol: Perkin Elmer Life Sciences Inc.)
and incubated for 3 min at 37°C in a water bath. The reaction was terminated using 1
ml of ice-cold choline buffer (incubation buffer in which an equimolar concentration
of choline chloride was substituted for NaCl), and the samples were centrifuged at
10,000 g for 2 min to recover synaptosomes. The 
3
H-bound radioactivity was
determined by liquid scintillation counting (PACKARD liquid scintillation analyzer
TRI-CARB 2200CA). Sodium dependent uptake was determined by subtracting the
signal obtained in the choline chloride buffer from that obtained in the presence of
sodium.
Glial cells and glutamate uptake
Glial cells were obtained from postnatal day (P) 1 brains of wild type and Per2
Brdm1
mutant pups. Cerebral hemispheres were dissected under sterile conditions and were
collected in 100 mm culture dishes containing ice-cold TBS. Dissected tissue pieces
were incubated for 20 min in Trypsin/EDTA at 37°C and 5% CO2. Trypsin action was
terminated by transferring the tissue pieces to DMEM (AMIMED) supplemented with
10% fetal calf serum. The tissue was dissociated gently by trituration through a sterile
plastic pipette and the cell suspension was centrifuged at 400 x g for 5 min and the
pellet was resuspended in DMEM supplemented with 10% fetal calf serum. Cells
were plated onto 100 mm culture dishes (NUNC ™ Brand Products). On reaching
confluency, the cultured cells were washed twice in TBS, trypsinized and replated.
After the second passage, the cells were counted and seeded into 24-welled plates for
the glutamate uptake assay.
Glutamate uptake was performed in either sodium or lithium-supplemented
Tris buffer containing 5 mM Tris base, 10mM HEPES, 140 mM NaCl or LiCl, 2.5
mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 1.2mM K2HPO4, 10 mM dextrose and the
glutamine synthetase inhibitor methionine sulfoximine (1mM; Sigma). Tritium-
labeled glutamate (specific activity 51 Ci/mmol; Perkin Elmer Life Sciences Inc.) and
unlabeled glutamate were mixed to obtain a total glutamate concentration of 960 µM.
The stock solution was further diluted with the respective uptake buffer to yield
working concentrations of 160, 80, 40, 20, 10 and 5 µM glutamate. Each well
received 250µl of the respective 
3
(H) glutamate solution and the uptake was
terminated after 10 min by removing the radioactive solution and rinsing the cultures
three times with ice-cold lithium-containing Tris buffer. Cells were then lysed in 0.1
M NaOH and the amount of incorporated glutamate was determined by liquid
scintillation counting (PACKARD liquid scintillation analyzer TRI-CARB 2200CA)
of the cell lysate. Sodium-dependent glutamate uptake was defined to be the
difference of the amount of radioactivity incorporated by the glia in the presence of
sodium- and lithium-containing buffer and normalized to the protein in the sister
cultures.
Microdialysis and determination of glutamate levels
Mice were anaesthetised with sodium pentobarbital (70mg/kg i.p.) and mounted on a
David Kopf stereotaxic frame. The body temperature was maintained during the
operation via a heating pad. The skull was exposed and one hole was made for
implanting the microdialysis guide cannula and another for the fixing microscrew,
both of which were cemented to the skull. The CMA/7 guide cannula with a dummy
was implanted into the ventral striatum (anterior-posterior, 1.1; lateral, ± 1.5; ventral,
- 3.5 mm).
After the implantation, the mice were placed in the CMA/120 system for
freely moving animals and connected via a collar to a swivel. The CMA/7
microdialysis probe (2-mm membrane length) was inserted into the guide cannula and
perfused at a constant flow rate of 2 µl/min with a Ringer solution containing 147mM
NaCl, 4mM KCl, 2.3mM CaCl2. One day after the recovery, microdialysis
experiments were carried out in freely moving mice between ZT3 and ZT6.
Dialysates were collected every 20 min. The first six samples were collected to
provide an estimation of basal extracellular levels of glutamate. The animals were
then treated with either saline or acamprosate (200mg/kg i.p.) and 8 additional
samples were collected every 20 min.
As previously described in detail48, glutamate levels were determined from 15-
µL of each dialysate sample. Briefly, a gradient microbore liquid chromatography
assay with fluorescence detection was used for glutamate after pre-column
derivatization with o-phtalaldehyde/-mercaptoethanol.
Determination of blood alcohol levels
Alcohol-naïve and alcohol-experienced wild type and Per2
Brdm1
 mutant mice
were injected i.p. with 3.5 g/kg ethanol. Blood alcohol levels were measured by
drawing blood samples (25-30 l) from the tip of the tail at various time points after
injection (30, 60, 120, and 240 min). Blood alcohol levels were also determined in
some animals following the alcohol self-administration procedure. Blood alcohol
content was determined using the NADH enzyme spectrophotometric method
(Greiner, Stuttgart, Germany).
C. Behavioural methods
Alcohol self-administration and pharmacological treatment
After one week of habituation to the animal room, male Per2
Brdm1
 mutant and
control mice were given continuous free access to two bottles of tap water for 3 days,
followed by tap water and 2% (v/v) ethanol solution for another 3 days (Days 1-3). At
all subsequent periods the mice had access to tap water as well as an ethanol solution
with increasing concentrations: days 4-6, the mice received 4% ethanol solution; days
7-16 access to 8% ethanol solution; days 17-25 12% solution; and 16% ethanol
solution from day 26 onward. Spillage and evaporation were minimized by the use of
self-made glass cannulae in combination with a small plastic bottle (Techniplast,
Milano, Italy). Under these conditions ethanol concentration in a given solution
stayed constant for at least 1 week, when measured with an alcoholometer (GECO,
Gering, Germany). Bottles were weighted daily at 10:00 a.m. and all drinking
solutions were renewed every 3 days and the positions of the 2 bottles changed to
avoid side preferences. Water and ethanol consumption as well as total fluid intake
were calculated in terms of ml of solution consumed/day (ml/day). Ethanol
consumption was calculated in terms of g of ethanol consumed/kg of body weight/day
(g/kg/day). Ethanol-drinking solutions consisted of 96% ethanol, diluted with tap
water to achieve the different concentrations.
In a second batch of mice, we tested the effects of acamprosate treatment.
Thus, 10 wild type and 10  Per2
Brdm1
 mutant mice were submitted to the alcohol
drinking protocol as described in the previous paragraph. Once alcohol intake at the
16% solution was stable, two daily injections of acamprosate (200 mg/kg, every 12:00
h) were given to all mice and drinking data were compared to those of the four last
days of the baseline. The drinking data were then transformed into a percentage
measure of the group differences and statistically analyzed by a two-way ANOVA.
Operant ethanol self-administration and PR measurements
Experiments were performed during the active phase in operant chambers (TSE
Systems, Bad Homburg, Germany) equipped with two levers, only one being active,
and individual sessions lasting 30 minutes. Animals (8 wild type and 8 Per2
Brdm1
mutant littermates) were trained to orally self-administer ethanol (10%) after having
undergone a standard sucrose fading procedure under a fixed ratio 1 (FR1) paradigm.
In essence, a single press of the active lever resulted in a yellow light being turned on
with a simultaneous delivery of 10 l of solution exactly underneath it. The time line
of operant self-administration consisted of an initial 10 days of  sucrose (5%) solution,
followed by 5 days of sucrose (5%) and ethanol (5%), 5 days of ethanol (5%), 5 days
of sucrose (5%) and ethanol (8%), 5 days of ethanol (8%), 10 days of sucrose (5 %)
and ethanol (10%). And, finally, ethanol (10%) only was introduced. Further, mice
were then tested on a progressive-ratio (PR) schedule for ethanol (10%)
reinforcement, in which the response requirements increased by a step size of 2. The
final ratio completed was defined as the breaking point.
Taste preference tests
Alcohol-naïve and alcohol-experienced mice were used for these tests. Sucrose (0.5,
2.5, and 5% w/v) and quinine (5,10, and 20 mg/dl) solution intake was measured in a
two-bottle free choice test (sucrose or quinine against water). A test lasted for 9 days
and bottles were weighed every 3 days along with the position of the bottles being
changed.
D. Genetic methods
Subjects and psychiatric assessment
215 patients of German origin (172 males, 43 females; mean age 41.3 years, SD 8.4)
were recruited by the Department of Psychiatry of the University of Munich. All
patients were consecutively admitted for an in-patient alcohol withdrawal therapy and
fulfilled the DSM-IV criteria for alcohol dependence. Symptoms related to alcohol
taking behaviour were assessed in using the semi-structured assessment for the
Genetics of Alcoholism (SSAGA)
37
. To distinguish patients with low vs. high alcohol
intake, a cut-off was set at 300g/d, ensuring comparability of the results with previous
work on genes regulating glutamatergic neurotransmission
38
. There was no significant
age difference between both groups and gender specific analysis revealed no effect of
gender on genotype (data not shown). Written informed consent was obtained from all
individuals, when they were in a state of full legal capacity. The study was approved
by the ethics committee of the University of Munich.
Mutation screening and promoter analysis
Identification of SNPs was performed by sequencing 32 Caucasian DNA samples. 16
DNA pools consisting of an equimolar mixture of two DNA samples were prepared
and used as PCR templates. For each gene, primers were chosen in order to amplify
the regulatory domains, the exon-containing DNA fragments, including exon-intron
boundaries. The PCRs were performed in a 15ul reaction mixture containing 25ng
DNA. The list of the primers for each gene is available on the web site of the CNG
(www.cng.fr). Sequencing reactions were performed using an ABI PRISM 3700 DNA
Analyzer (Applied Biosystems, Foster City, CA). Alignment of experimental results
and identification of SNPs were done using the Genalys software developed by the
CNG.
Genotype analysis
DNA was prepared from whole blood with standard salting out methods. Six Single-
nucleotide polymorphisms in the PER2 gene were genotyped using the TaqMan MGB
biallelic discrimination system. Probes and primers were ordered from and
automatically designed by Applied Biosystems using the Assay-by-Design product.
PCR reactions were performed in Biometra T1 thermocyclers, and fluorescence
results were determined with the use of an ABI Prism 7900HT sequence-detector end-
point read. Process and genotyping data were exported into an internal LIM System.
Complete genotypes were obtained from 200 patients, which were included in the
haplotype analysis.
Association analysis and haplotype analysis
The p-values of genotypes reported refer to the two-sided trend test for 2x3
contingency tables as originally proposed by Armitage
49
. Haplotype association
analyses were performed with COCAPHASE 2.35
 
(www.hgmp.mrc.ac.uk). This
package performs likelihood ratio tests under a log-linear model of the probability that
an allele or haplotype belongs to the case rather than control group, using a standard
unconditional logistic regression. In COCAPHASE the EM algorithm is used to
provide maximum-likelihood estimates of frequencies. Since the EM algorithm does
not accurately estimate haplotype frequencies below 1%, haplotypes <1% in either
group were excluded.
Stepwise regression analysis was performed using the stepwise regression
procedure by forwarding from SAS version 8.2. SNP3 was the first variable to be
included. Significance level for entry was 0.05.
For the haplotype analyses, the global null hypotheses that all odds ratios are
equal were also tested by permutation, owing to the fact that estimated haplotype
frequencies cannot be treated as observed data. The method randomly reassigns the
‘case’ and ‘control’ labels in the actual data. The permutation procedure gives a
significance level corrected for all markers or haplotypes tested. 10,000 permutations
were performed for the haplotype tests (for this test p-value is assigned as global p-
value). When the global test was significant, individual haplotypes were tested for
association by grouping all others together and applying the 2-test with 1 df.
Supplementary Table 1: Distribution of genotypes and results of
association tests for alcohol dependent patients with high (300g/d) and
low alcohol intake (<300g/d).
Groups for
every marker
Cases
genotype
d
Distribution
of
Genotypes
p-value
Armitage- trend Test
(z-Values)
Odds Ratio
2.Allel vs. 1. Allel
[Conf. Interv.]
2 (SNP 10553) CC CG GG
Low alcohol intake 114 91 (79,82%) 21 (18,42%) 2 (1,75%)
High alcohol intake 95 81 (85,26%) 13 (13,68%) 1 (1,05%)
0.335
(1.032)
0.696
[0.356-1.346]
3 (SNP 10870) AA AG GG
Low alcohol intake 116 82 (70,69%) 30 (25,86%) 4 (3,45%)
High alcohol intake 96 80 (83,33%) 16 (16,67%) 0 (0,00%)
0.020
(2.445)
0.464
[0.250-0.861]
4 (SNP 10562) CC CT TT
Low alcohol intake 112 13 (11,61%) 38 ()33,93% 61 (54,46%)
High alcohol intake 94 4 (4,26%) 34 (36,17%) 56 (59,57%)
0.196
(-1.383)
1.391
[0.887-2.179]
5 (SNP 10563) CC CT TT
Low alcohol intake 116 92 (79,31%) 22 (18,97%) 2 (1,72%)
High alcohol intake 95 81 (85,26%) 13 (13,68%) 1 (1,05%)
0.3364
(1.113)
0.679
[0.349-1.323]
9 (SNP 10565) CC CG GG
Low alcohol intake 116 114 (98,28%) 2 (1,72%) 0 (0,00%)
High alcohol intake 96 90 (93,75%) 6 (6,25%) 0 (0,00%)
0.1447
(-1.721)
3.704
[0.740-18.519]
11 (SNP 10559) CC CT TT
Low alcohol intake 116 114 (98,28%) 2 (1,72%) 0 (0,00%)
High alcohol intake 96 90 (93,75%) 6 (6,25%) 0 (0,00%)
0.1447
(-1.721)
3.704
[0.740-18.519]
Supplementary Table 2: Results of haplotype analysis
low alcohol
intake
high alcohol
intake
Global p-value =
0.0363
1
Haplotype freq freq
Odds
Ratio
2
95%-Confidence
Interval (OR)
p-value individual
haplotypes
(Chi-Square)
G-C-C-C 0.1525 0.0710 0.42 0.22 –0.83 0.0075 (2=7.141)
A-C-C-C 0.0368 0.0613 1.71 0.67 – 4.33 0.2679 (2=1.228)
A-C-T-C 0.0963 0.0766 0.78 0.38 – 1.58 0.4914 (2=0.4734)
A-T-C-C 0.7004 0.7463 1.26 0.81 – 1.96 0.2657 (2=1.239)
All frequent 0.9861 0.9552
All rare
3
0.0139 0.0448
1
Based on 10,000 permutation
2
Odds ratio calculated for each haplotype vs. all others.
3
contains all haplotypes <1% in either group (alcoholics with low or high alcohol intake)
